The cost of a euploid embryo identified from preimplantation genetic testing for aneuploidy (PGT-A): a counseling tool.

J Assist Reprod Genet

Center for Infertility and Reproductive Surgery, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.

Published: September 2018

AI Article Synopsis

  • The study aims to estimate the out-of-pocket costs for couples undergoing IVF with preimplantation genetic testing for aneuploidy (PGT-A) in order to achieve varying likelihoods of obtaining a euploid blastocyst, depending on the patient's age and AMH levels.
  • A cost analysis was conducted using historical IVF data, employing statistical methods to simulate costs and likelihoods, and the findings show significant variations in costs based on age and AMH levels, ranging from approximately $15,000 to over $450,000.
  • The developed counseling tool offers personalized financial insights for patients, assisting them in understanding the potential costs associated with achieving different success rates in obtaining healthy embryos.

Article Abstract

Purpose: To determine the expected out-of-pocket costs of IVF with preimplantation genetic testing for aneuploidy (PGT-A) to attain a 50%, 75%, or 90% likelihood of a euploid blastocyst based on individual age and AMH, and develop a personalized counseling tool.

Methods: A cost analysis was performed and a counseling tool was developed using retrospective data from IVF cycles intended for PGT or blastocyst freeze-all between January 1, 2014 and August 31, 2017 (n = 330) and aggregate statistics on euploidy rates of > 149,000 embryos from CooperGenomics. Poisson regression was used to determine the number of biopsiable blastocysts obtained per cycle, based on age and AMH. The expected costs of attaining a 50%, 75%, and 90% likelihood of a euploid blastocyst were determined via 10,000 Monte Carlo simulations for each age and AMH combination, incorporating age-based euploidy rates and IVF/PGT-A cost assumptions.

Results: The cost to attain a 50% likelihood of a euploid blastocyst ranges from approximately $15,000 U.S. dollars (USD) for younger women with higher AMH values (≥ 2 ng/mL) to > $150,000 for the oldest women (44 years) with the lowest AMH values (< 0.1 ng/mL) in this cohort. The cost to attain a 75% versus 90% likelihood of a euploid blastocyst is similar (~ $16,000) for younger women with higher AMH values, but varies for the oldest women with low AMH values (~ $280,000 and > $450,000, respectively). A typical patient (36-37 years, AMH 2.5 ng/mL) should expect to spend ~ $30,000 for a 90% likelihood of attaining a euploid embryo.

Conclusions: This tool can serve as a counseling adjunct by providing individualized cost information for patients regarding PGT-A.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133815PMC
http://dx.doi.org/10.1007/s10815-018-1275-5DOI Listing

Publication Analysis

Top Keywords

90% likelihood
12
likelihood euploid
12
euploid blastocyst
12
age amh
12
preimplantation genetic
8
genetic testing
8
testing aneuploidy
8
aneuploidy pgt-a
8
counseling tool
8
attain 50%
8

Similar Publications

Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort.

Liver Int

February 2025

General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China.

Background And Aims: Cirrhosis is characterised by hyperdynamic circulation, which contributes to cirrhotic cardiomyopathy (CCM). However, the expert consensus on CCM did not initially include cardiac structure because of scant evidence. Therefore, this study investigated the associations of cardiac chamber geometry with mortality and CCM.

View Article and Find Full Text PDF

Exposure to School Racial Segregation and Late-Life Cognitive Outcomes.

JAMA Netw Open

January 2025

Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.

Importance: Disparities in cognition, including dementia occurrence, persist between non-Hispanic Black (hereinafter, Black) and non-Hispanic White (hereinafter, White) older adults, and are possibly influenced by early educational differences stemming from structural racism. However, the association between school racial segregation and later-life cognition remains underexplored.

Objective: To investigate the association between childhood contextual exposure to school racial segregation and cognitive outcomes in later life.

View Article and Find Full Text PDF

Background: Examining the neuropathology of the oldest-old has significantly advanced our understanding of the multiple etiologies in very late life. Most studies have included exclusively White decedents with limited ethnoracial diversity. Our goal was to characterize neuropathology in a cohort of ethnically and racially diverse oldest-old decedents.

View Article and Find Full Text PDF

Background: Cerebrovascular disease (CVD) is a major cause of mortality in females, while two-thirds of Alzheimer's disease (AD) patients are female. AD and CVD share many genetic risk factors, one of them being apolipoprotein E (APOE) genotype. Sex differences in APOE and AD are well-established; it is unclear if associations between APOE and CVD are sex-specific.

View Article and Find Full Text PDF

Background: APOE e4 has been used to evaluate the risk for Alzheimer's diseases (AD) but there exist other AD risk genes, and their effects can be collectively measured by polygenic risk scores (PRS). In this study, we sought to use both PRS (APOE excluded) and APOE e4 to evaluate the AD risk.

Method: The discovery dataset was meta-analysis of three large-scale European ancestry AD GWAS (Kunkle et al, 2019, the UK Biobank, and the FinnGen consortium).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!